Novo Reports Strong Results for Next Obesity Shot
Novo Nordisk says its new weight loss drug helped women lose 25% of their body weight in a late trial.
The race to make better weight loss drugs moves fast. Drugmaker Novo Nordisk already sells Wegovy. Now the company has a new shot that works even better.
The new shot is called CagriSema. Fresh study data shows strong results. Women in the late trial lost a full quarter of their body weight. That tops the numbers from older treatments.
The injection combines two different medicines into one dose. It calms hunger signals in the brain and slows digestion. Patients stay full longer and eat less food.
Better drugs mean more choices for millions of people. This win keeps Novo ahead of its rivals. Strong trial results could keep the company growing for years to come.
Source: CNBC
More from Biotech
